Fig. 1From: Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern IndiaPercentage of patients showing response and remission during escitalopram therapy. Overall: total study population (n = 148). Group 1: baseline HDRS-17 score between 18 and 23 (n = 91). Group 2—HDRS 17 score ≥ 24 (n = 57)Back to article page